PDSB supply chain intelligence for PDS Biotechnology Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
PDS Biotechnology Corporation (PDSB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NATIONAL-INSTITUTES-OF-HEALTH | NATIONAL-INSTITUTES-OF-HEALTH | 92% | NIH granted us a nonexclusive license to certain patent rights |
| YA-II-PN-LTD | YA-II-PN-LTD | 92% | Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investor and the Investor agreed to purchase from the Company |
| MERCK-EPROVA-AG | MERCK-EPROVA-AG | 90% | we entered into a DOTAP Chloride Enantiomer License with Merck Eprova AG |
| NCI | Neo-Concept International Group Holdings Limited | 90% | Reciprocal relationship from NCI graph: Reciprocal relationship from PDSB graph: we obtained a nonexclusive, worldwide license to the patent rights for TARP to develop and commercialize TARP peptide-… |
| NCI | Neo-Concept International Group Holdings Limited | 90% | we obtained a nonexclusive, worldwide license to the patent rights for TARP to develop and commercialize TARP peptide-based therapies |
| YORKVILLE-SECURITIES-LLC | YORKVILLE-SECURITIES-LLC | 90% | the Company will enter into a Sales Agreement with Yorkville Securities, LLC ("Agent"), as sales agent, with respect to an at-the-market offering program |
| JGB-COLLATERAL-LLC | JGB-COLLATERAL-LLC | 85% | In April 2025, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain third-party lenders and JGB Collateral LLC, as collateral agent. |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (the “CTCSA”) with MSD International GmbH (“Merck”) pursuant to which we and Merck a… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from PDSB graph: SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (t… |
| JNJ | Johnson & Johnson | 72% | SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (the “CTCSA”) with MSD International GmbH (“Merck”) pursuant to which we and Merck a… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from PDSB graph: SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (th… |
| SNYNF | Sanofi | 72% | SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (the “CTCSA”) with MSD International GmbH (“Merck”) pursuant to which we and Merck a… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from PDSB graph: SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (… |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: Reciprocal relationship from PDSB graph: Reciprocal relationship from XLO graph: Reciprocal relationship from PDSB graph: Reciprocal relationship from XLO grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HRZN | Horizon Technology Finance Corporation | 72% | Reciprocal relationship from HRZN graph: Reciprocal relationship from PDSB graph: Reciprocal relationship from HRZN graph: Reciprocal relationship from PDSB graph: Reciprocal relationship from HRZN g… |
| HRZN | Horizon Technology Finance Corporation | 72% | ed In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expe… |
| B-RILEY-SECURITIES-INC | B-RILEY-SECURITIES-INC | 62% | ed In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expe… |
| BTIG-LLC | BTIG-LLC | 62% | ed In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expe… |
| CO-LLC | CO-LLC | 62% | ed In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expe… |
| JGB-COLLATERAL-LLC | JGB-COLLATERAL-LLC | 62% | pment activities are expensed as incurred . We expect that our research and development expenses will increase significantly over the next several years as we advance our Versamune® and PDS01ADC prod… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PDSB-DEBT-11716 | Warrants outstanding: 381625 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| PDSB-DEBT-11717 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| PDSB-DEBT | Debt stack $15.0M | 90% | Market cache reports total debt of $15.0M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PDSB-OWNER-RENAISSANCE-TECHNOLOGIES-LLC | Renaissance Technologies, LLC | 95% | 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 176,700; ownership 0.32%; value $180,233; as of 2025-12-31. |
| PDSB-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 522,211; ownership 0.94%; value $532,655; as of 2025-12-31. |
| PDSB-OWNER-ARMISTICE-CAPITAL-LLC | Armistice Capital, LLC | 95% | 13F/ownership overlay lists Armistice Capital, LLC; shares held 2,834,506; ownership 5.08%; value $2.9M; as of 2025-12-31. |
| PDSB-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 1,950,946; ownership 3.50%; value $2.0M; as of 2025-12-31. |
| PDSB-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 520,398; ownership 0.93%; value $530,805; as of 2025-12-31. |
| PDSB-OWNER-BLAIR-WILLIAM-CO-IL | BLAIR WILLIAM & CO/IL | 95% | 13F/ownership overlay lists BLAIR WILLIAM & CO/IL; shares held 250,000; ownership 0.45%; value $254,999; as of 2025-12-31. |
| PDSB-OWNER-COMMONWEALTH-EQUITY-SERVICES-LLC | Commonwealth Equity Services, LLC | 95% | 13F/ownership overlay lists Commonwealth Equity Services, LLC; shares held 196,797; ownership 0.35%; value $200,732; as of 2025-12-31. |
| PDSB-OWNER-SQUAREPOINT-OPS-LLC | Squarepoint Ops LLC | 95% | 13F/ownership overlay lists Squarepoint Ops LLC; shares held 192,556; ownership 0.34%; value $196,407; as of 2025-12-31. |
| PDSB-OWNER-INSPIRION-WEALTH-ADVISORS-LLC | Inspirion Wealth Advisors LLC | 95% | 13F/ownership overlay lists Inspirion Wealth Advisors LLC; shares held 180,495; ownership 0.32%; value $184,104; as of 2025-12-31. |
| PDSB-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 251,705; ownership 0.45%; value $256,739; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| NCI | Neo-Concept International Group Holdings Limited | 100.00 | 1 | ['supplier'] |
| CBLL | CeriBell, Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| PTHS | Pelthos Therapeutics Inc. | 100.00 | 2 | |
| XLO | Xilio Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| JANX | Janux Therapeutics, Inc. | 100.00 | 2 | |
| HRZN | Horizon Technology Finance Corporation | 100.00 | 1 | ['customer'] |
| SNYNF | Sanofi | 100.00 | 1 | ['supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['supplier'] |
| VIR | Vir Biotechnology, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 50.00 | 2 | |
| ENGNW | enGene Therapeutics Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 |